Objective:Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs.Participants:Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts. Funding was via an unrestricted educational grant from Astra Zeneca to the Pediatric Endocrine Society. Meetings were not open to the general public.Evidence:A literature review was conducted by the committee. Recommendations of the committee were graded using the system of the American Heart Association. Expert opinion was used when published data were unavailable or scarce.Consensus Process:The guideline was drafted by committee members and reviewed, revised, and approved by the entire committee during group meetings. Contributing societies reviewed the document and provided approval.Conclusions:Lipodystrophy syndromes are heterogeneous and are diagnosed by clinical phenotype, supplemented by genetic testing in certain forms. Patients with most lipodystrophy syndromes should be screened for diabetes, dyslipidemia, and liver, kidney, and heart disease annually. Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabetes, and statins or fibrates for hyperlipidemia). Oral estrogens are contraindicated.
Inherited defects in signaling pathways downstream of the insulin receptor have long been suggested to contribute to human Type 2 diabetes mellitus. Here we describe a mutation in the gene encoding the protein kinase AKT2/PKBβ in a family that shows autosomal dominant inheritance of severe insulin resistance and diabetes mellitus. Expression of the mutant kinase in cultured cells disrupted insulin signaling to metabolic end-points and inhibited the function of coexpressed, wild type AKT. These findings demonstrate the central importance of AKT signaling to insulin sensitivity in humans.Most forms of diabetes are likely to be polygenic in origin, although a number of monogenic forms are being recognised (1, 2). Although rare, these monogenic examples offer insights into the function of the affected gene in humans as well as offering important clues to understanding more common forms.We have been screening genomic DNA from 104 unrelated subjects with severe insulin resistance for mutations in genes that are implicated in insulin signalling. We identified a † To whom correspondence should be addressed. E-mail: sorahill@hgmp.mrc.ac.uk. * These authors contributed equally to this work. Europe PMC Funders Group Europe PMC Funders Author ManuscriptsEurope PMC Funders Author Manuscripts missense mutation in the serine/threonine kinase gene AKT2 in one Caucasian proband.AKT2 (also known as PKBβ) is highly expressed in insulin sensitive tissues and is activated in response to growth factors and related stimuli (3, 4) a process that requires its phosphorylation by the phosphoinositide-3 phosphate-dependent kinase activities designated PDK1 and PDK2 (3). The proband, (iii)/1 (Fig. 1D), is a non-obese 34 year old female who developed diabetes mellitus at 30 years of age. The proband, her non-obese mother, (ii)/2, maternal grandmother, (i)/2, and a maternal uncle, (ii)/3, were all heterozygous for a G to A substitution predicted to result in an R to H substitution at amino acid 274 (Fig. 1 A, B). All were markedly hyperinsulinemic (Table S1) and the mother and maternal grandmother developed diabetes mellitus in their late 30′s. Three other first-degree relatives available for study were all clinically normal with normal fasting glucose and insulin and were homozygous for the wild-type AKT2 sequence ( Fig. 1D and Table S1). This mutation was not found in genomic DNA of 1500 Caucasian control subjects from the UK.R274 forms part of an RD sequence motif within the catalytic loop of the AKT2 kinase domain that is invariant in AKT isoforms in all species, and is also highly conserved within the protein kinase family (Fig. 1C) (5). The RD motif includes the invariant D residue (D275 of AKT2) that performs an essential catalytic function in all protein kinases.R274 is positioned in the core of the catalytic domain, forming critical hydrogen bonds with the phosphate moiety of phosphoT309 in the activation segment permitting correct positioning the substrate peptide relative to the catalytic base and adenosine triphosphate (A...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.